Polymorphisms in the CYP3A gene or other genetic loci controlling expression and function of CYP3A4 may explain the person-to-person variations seen in intensity and duration of drug action ...

A new report from an international consortium provides comprehensive scientific recommendations for studies of transporter-related drug interactions in drug development. In March 2004, the US FDA ...

The drug is cleared by cytochrome P450 (CYP ... Blood levels of eplerenone are increased by inhibitors of CYP3A4, such as ketoconazole and saquinavir. About 50% is bound by plasma protein.

The drug, which combines the compounds nirmatrelvir ... mg dose of ritonavir twice a day for 5 days. Ritonavir binds with CYP3A4 enzymes, which are responsible for metabolism, and gives ...

Potentiated by CYP3A4 inhibitors (eg ... Prior adverse hematologic reaction to any drug. Do baseline CBCs then periodically; discontinue if significant bone marrow depression occurs.

Conversion from other opioids: see full labeling. Concomitant use or discontinuation of CYP2D6 inhibitors, CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full ...